Edwards Lifesciences Raises Full-Year Sales and EPS Guidance on Strong Q1 Performance

summarizeSummary

Edwards Lifesciences reported robust first-quarter results, with sales growing 16.7% and adjusted EPS of $0.78, leading the company to raise its full-year 2026 sales and adjusted EPS guidance.

check_boxKey Events

• Strong Q1 Financial Performance

  Edwards Lifesciences reported first-quarter sales growth of 16.7% to $1.65 billion (12.7% constant currency) and adjusted diluted EPS of $0.78, demonstrating robust operational execution.

• Raised Full-Year 2026 Guidance

  The company raised its full-year 2026 constant currency sales growth guidance to 9-11% (from 8-10%) and increased the midpoint of its adjusted EPS guidance to a new range of $2.95-$3.05 (from $2.90-$3.05), reflecting increased confidence in future performance.

• Accelerated Share Repurchase Completed

  Edwards Lifesciences completed a $500 million accelerated share repurchase agreement during the quarter, with approximately $1.5 billion remaining under its current authorization.

• Strategic Product Portfolio Growth

  The TAVR segment saw 14.4% sales growth, and TMTT sales reached $173 million, driven by strong adoption of therapies like SAPIEN TAVR, EVOQUE, PASCAL, and the recently FDA-approved SAPIEN M3.

auto_awesomeAnalysis

Edwards Lifesciences delivered robust first-quarter results, exceeding expectations and prompting an upward revision of its full-year 2026 sales and adjusted EPS guidance. This positive outlook, driven by strong performance across its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments, signals management's confidence in continued growth. The completion of a significant accelerated share repurchase program further enhances shareholder value. While the company reported a non-cash impairment loss, the overall financial strength and improved guidance are the dominant market-moving factors, suggesting a positive trajectory for the company's core business.